DDO-2093

Cat. No.:	HY-132233
CAS No.:	2250024-74-7
Molecular Formula:	$C_{29}H_{37}ClFN_9O_3$
Molecular Weight:	614.11
Target:	Histone Methyltransferase
Pathway:	Epigenetics
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description

DDO-2093 is a potent MLL1-WDR5 protein-protein interaction inhibitor (IC_{50}=8.6 nM; K_d=11.6 nM) with antitumor activity. DDO-2093 selectively inhibits the catalytic activity of MLL complex[1].

In Vitro

DDO-2093 (5 μM; pretreated 7 days) inhibits MLL-fusion protein dependent genes expression (HOXA9 and Meis1)[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis[1]

Cell Line:	MV4-11 cells
Concentration:	1, 2.5, 5, and 10 μM
Incubation Time:	7 days
Result:	Dose-dependently reduced the mono-, di-, and trimethylation of H3K4.

In Vivo

DDO-2093 (20-80 mg/kg; i.p.; every other day for 21 days) significantly suppresses the tumor size and weight in a dose-dependent manner[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Female nude mice (MV4-11 human leukemia cancer xenografts)[1]
Dosage:	20 mg/kg, 40 mg/kg and 80 mg/kg
Administration:	Intraperitoneal injection; every other day for 21 days
Result:	Had the tumor volume growth inhibition (GI) values were calculated to be 13.7%, 37.6% and 63.9% with doses of 20 mg/kg, 40 mg/kg and 80 mg/kg, respectively.

REFERENCES

[1]. Chen W, et al. Discovery of a potent MLL1 and WDR5 protein-protein interaction inhibitor with in vivo antitumor activity [published online ahead of print, 2021 Jun 28]. Eur J Med Chem. 2021;223:113677.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA